273 related articles for article (PubMed ID: 24280444)
1. Minimum effective dosages of anti-TNF in rheumatoid arthritis: a cross-sectional study.
de la Torre I; Valor L; Nieto JC; Montoro M; Carreño L
Reumatol Clin; 2014; 10(2):101-4. PubMed ID: 24280444
[TBL] [Abstract][Full Text] [Related]
2. Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis.
Oladapo A; Barner JC; Lawson KA; Novak S; Rascati KL; Richards KM; Harrison DJ
J Manag Care Spec Pharm; 2014 Jul; 20(7):657-67. PubMed ID: 24967519
[TBL] [Abstract][Full Text] [Related]
3. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
[TBL] [Abstract][Full Text] [Related]
4. Influence on effectiveness of early treatment with anti-TNF therapy in rheumatoid arthritis.
Escudero-Vilaplana V; Ramírez-Herraiz E; Trovato-López N; Alañón-Plaza E; Bellini MJ; Herranz-Alonso A; Bellón-Cano JM; Morell-Baladrón A; Sanjurjo-Sáez M
J Pharm Pharm Sci; 2012; 15(3):355-60. PubMed ID: 22974785
[TBL] [Abstract][Full Text] [Related]
5. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.
Malottki K; Barton P; Tsourapas A; Uthman AO; Liu Z; Routh K; Connock M; Jobanputra P; Moore D; Fry-Smith A; Chen YF
Health Technol Assess; 2011 Mar; 15(14):1-278. PubMed ID: 21439251
[TBL] [Abstract][Full Text] [Related]
6. The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study.
Moots RJ; Xavier RM; Mok CC; Rahman MU; Tsai WC; Al-Maini MH; Pavelka K; Mahgoub E; Kotak S; Korth-Bradley J; Pedersen R; Mele L; Shen Q; Vlahos B
PLoS One; 2017; 12(4):e0175207. PubMed ID: 28448562
[TBL] [Abstract][Full Text] [Related]
7. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry.
Atzeni F; Sarzi-Puttini P; Botsios C; Carletto A; Cipriani P; Favalli EG; Frati E; Foschi V; Gasparini S; Giardina A; Gremese E; Iannone F; Sebastiani M; Ziglioli T; Biasi D; Ferri C; Galeazzi M; Gerli R; Giacomelli R; Gorla R; Govoni M; Lapadula G; Marchesoni A; Salaffi F; Punzi L; Triolo G; Ferraccioli G
Autoimmun Rev; 2012 Dec; 12(2):225-9. PubMed ID: 22796281
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of TNF-α blocker immunogenicity in psoriatic arthritis.
Zisapel M; Zisman D; Madar-Balakirski N; Arad U; Padova H; Matz H; Maman-Sarvagyl H; Kaufman I; Paran D; Feld J; Litinsky I; Wigler I; Caspi D; Elkayam O
J Rheumatol; 2015 Jan; 42(1):73-8. PubMed ID: 25399390
[TBL] [Abstract][Full Text] [Related]
9. Sustained Remission in Tumor Necrosis Factor Inhibitor-treated Patients with Rheumatoid Arthritis: A Population-based Cohort Study.
Einarsson JT; Geborek P; Saxne T; Kapetanovic MC
J Rheumatol; 2015 May; 42(5):741-8. PubMed ID: 25684762
[TBL] [Abstract][Full Text] [Related]
10. Infliximab efficacy in rheumatoid arthritis after an inadequate response to etanercept or adalimumab: results of a target-driven active switch study.
Fleischmann R; Goldman JA; Leirisalo-Repo M; Zanetakis E; El-Kadi H; Kellner H; Bolce R; DeHoratius R; Wang J; Decktor D
Curr Med Res Opin; 2014 Nov; 30(11):2139-49. PubMed ID: 25050591
[TBL] [Abstract][Full Text] [Related]
11. Economical impact associated with a biological therapy prioritization protocol in patients with rheumatoid arthritis in the Hospital of Sagunto.
Borrás-Blasco J; Casterá MD; Cortes X; Rosique-Robles JD; Abad FJ
Expert Opin Biol Ther; 2014 Nov; 14(11):1561-7. PubMed ID: 25303321
[TBL] [Abstract][Full Text] [Related]
12. Switching from an anti-TNF monoclonal antibody to soluble TNF-receptor yields better results than vice versa: An observational retrospective study of 72 rheumatoid arthritis switchers.
Lequerré T; Farran É; Ménard JF; Kozyreff-Meurice M; Vandhuick T; Tharasse C; Pouplin S; Daragon A; Le Loët X; Varin R; Vittecoq O
Joint Bone Spine; 2015 Oct; 82(5):330-7. PubMed ID: 25864942
[TBL] [Abstract][Full Text] [Related]
13. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
Ollendorf DA; Klingman D; Hazard E; Ray S
Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
[TBL] [Abstract][Full Text] [Related]
14. Persistent periodontal disease hampers anti-tumor necrosis factor treatment response in rheumatoid arthritis.
Savioli C; Ribeiro AC; Fabri GM; Calich AL; Carvalho J; Silva CA; Viana VS; Bonfá E; Siqueira JT
J Clin Rheumatol; 2012 Jun; 18(4):180-4. PubMed ID: 22647860
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival.
Flouri I; Markatseli TE; Voulgari PV; Boki KA; Papadopoulos I; Settas L; Zisopoulos D; Skopouli FN; Iliopoulos A; Bertsias GK; Geborek P; Drosos AA; Boumpas DT; Sidiropoulos P
Semin Arthritis Rheum; 2014 Feb; 43(4):447-57. PubMed ID: 24012040
[TBL] [Abstract][Full Text] [Related]
16. Reduction of biological agent dose in rheumatic diseases: descriptive analysis of 153 patients in clinical practice conditions.
Inciarte-Mundo J; Hernández MV; Rosario V; Ruiz-Esquide V; Cabrera-Villalba S; Ramírez J; Cañete JD; Sanmartí R
Reumatol Clin; 2014; 10(1):10-6. PubMed ID: 23876791
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis.
Fernández-Nebro A; Irigoyen MV; Ureña I; Belmonte-López MA; Coret V; Jiménez-Núñez FG; Díaz-Cordovés G; López-Lasanta MA; Ponce A; Rodríguez-Pérez M; Calero E; González-Santos P
J Rheumatol; 2007 Dec; 34(12):2334-42. PubMed ID: 17985409
[TBL] [Abstract][Full Text] [Related]
18. Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance.
Cantini F; Niccoli L; Goletti D
J Rheumatol Suppl; 2014 May; 91():47-55. PubMed ID: 24789000
[TBL] [Abstract][Full Text] [Related]
19. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.
Finckh A; Simard JF; Gabay C; Guerne PA;
Ann Rheum Dis; 2006 Jun; 65(6):746-52. PubMed ID: 16339288
[TBL] [Abstract][Full Text] [Related]
20. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
Carter CT; Changolkar AK; Scott McKenzie R
J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
